Visceral fat is a type of deep abdominal fat that surrounds vital internal organs, including the liver, pancreas, and intestines. Unlike subcutaneous fat — the kind you can pinch beneath the skin — visceral fat is metabolically active, releasing hormones and inflammatory compounds that can significantly affect your health. Understanding what visceral fat is, where it accumulates, and why it matters is essential for assessing your true cardiometabolic risk. This article explains the science behind visceral fat, how it is measured in UK clinical practice, the health conditions it is linked to, and the evidence-based lifestyle changes that can help reduce it.

What Is Visceral Fat and How Does It Differ From Other Body Fat

Visceral fat is deep abdominal fat stored around internal organs that is metabolically active, releasing fatty acids and inflammatory compounds; unlike subcutaneous fat, it contributes disproportionately to insulin resistance and systemic inflammation.

Visceral fat is a specific type of body fat stored deep within the abdominal cavity, surrounding vital internal organs such as the liver, pancreas, and intestines. Unlike other forms of fat, it is metabolically active, meaning it releases hormones, fatty acids, and inflammatory compounds into the bloodstream. Intra-peritoneal visceral fat depots — such as omental and mesenteric fat — drain largely via the portal circulation, delivering these substances directly to the liver. Other visceral depots, such as perirenal (retroperitoneal) fat, drain into the systemic circulation. This biological activity distinguishes visceral fat from other fat types and contributes significantly to its health implications.

The body stores fat in two principal ways. Subcutaneous fat sits just beneath the skin and can be felt by pinching the skin at the abdomen, thighs, or arms. While excess subcutaneous fat can contribute to obesity-related conditions, it is generally considered less harmful than visceral fat. Visceral fat, by contrast, lies deeper and cannot be felt externally, making it harder to detect without specific measurements.

A key distinction lies in how each fat type behaves metabolically. Visceral fat cells are more sensitive to lipolysis (the breakdown of fat into fatty acids) and are more resistant to insulin signalling. This means visceral fat contributes disproportionately to insulin resistance, dyslipidaemia, and systemic inflammation — all of which are recognised risk factors for serious chronic disease. Understanding this difference is important because a person may appear to have a healthy body weight yet still carry a clinically significant amount of visceral fat. Researchers sometimes describe this as a 'metabolically unhealthy normal-weight' phenotype — a research term rather than a formal clinical diagnosis, but one that highlights why assessing fat distribution matters beyond body weight alone.

Where Visceral Fat Is Stored in the Body

Visceral fat accumulates primarily in the omentum and mesentery (intra-peritoneal depots) and around the kidneys (retroperitoneal), with distribution influenced by sex, age, genetics, and lifestyle factors.

Visceral fat is located within and around the abdominal cavity. It accumulates primarily in the omentum (a large fold of fatty tissue that drapes over the intestines) and the mesentery (the tissue connecting the intestines to the abdominal wall) — both of which are intra-peritoneal structures whose venous drainage feeds largely into the portal circulation. Visceral fat also accumulates in retroperitoneal depots, most notably around the kidneys (perirenal fat), which drain into the systemic circulation. Because of these deep anatomical locations, visceral fat is entirely internal and not visible or palpable from the outside.

The distribution of visceral fat varies between individuals and is influenced by several factors, including:

• Sex: Men tend to accumulate visceral fat more readily than pre-menopausal women, who are more likely to store fat subcutaneously in the hips and thighs. After the menopause, women's visceral fat accumulation increases significantly due to declining oestrogen levels.

• Age: Visceral fat naturally increases with age, even in individuals whose overall body weight remains stable.

• Genetics: Family history and genetic predisposition play a role in where the body preferentially stores fat.

• Lifestyle factors: Physical inactivity, poor dietary habits, chronic stress, and disrupted sleep are all associated with increased visceral fat deposition.

It is worth noting that fat can also accumulate around the heart (pericardial fat) and within the liver itself. Excess fat in the liver is known as non-alcoholic fatty liver disease (NAFLD) — a term still widely used in NHS and NICE materials. In recent international consensus, the condition has also been referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), and both terms may be encountered in UK clinical practice. This broader pattern of ectopic fat deposition further underscores the systemic nature of visceral fat accumulation.

Health Risks Associated With High Visceral Fat Levels

High visceral fat is strongly linked to type 2 diabetes, cardiovascular disease, NAFLD/MASLD, obstructive sleep apnoea, and certain cancers, largely due to its release of inflammatory cytokines and free fatty acids.

Elevated visceral fat is strongly associated with a range of serious health conditions, largely because of its metabolic activity. The free fatty acids and inflammatory cytokines it releases — including tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) — are associated with chronic low-grade inflammation and insulin resistance throughout the body. These processes are central to the development of metabolic syndrome, a cluster of conditions that significantly raises the risk of cardiovascular disease and type 2 diabetes.

The key health risks linked to high visceral fat include:

• Type 2 diabetes: Visceral fat is associated with impaired insulin sensitivity in the liver and peripheral tissues, which can raise blood glucose levels over time.

• Cardiovascular disease: Raised visceral fat is associated with hypertension, elevated LDL cholesterol, reduced HDL cholesterol, and increased triglycerides — all established cardiovascular risk factors recognised in NICE guidance on cardiovascular disease risk assessment and management.

• Non-alcoholic fatty liver disease (NAFLD/MASLD): Excess fat infiltrating the liver can progress to inflammation (steatohepatitis), fibrosis, and cirrhosis.

• Certain cancers: Research indicates associations between excess central adiposity and increased risk of colorectal, post-menopausal breast, and endometrial cancers, though the nature of these relationships is complex and causality is not fully established. NHS and Cancer Research UK resources provide further information on obesity and cancer risk.

• Obstructive sleep apnoea (OSA): Central obesity and increased neck circumference — which often accompany high visceral fat — are recognised risk factors for OSA, as noted in NICE guideline NG202 on obstructive sleep apnoea/hypopnoea syndrome in adults.

Importantly, these risks are not solely determined by overall body weight. NICE guidance on obesity acknowledges that central adiposity — even in individuals with a BMI within the 'healthy' range — can carry significant clinical risk. This reinforces the importance of assessing fat distribution rather than relying on weight alone.

How to Measure and Assess Visceral Fat

Waist circumference is the most practical clinical measure; NHS thresholds of ≥94 cm in men and ≥80 cm in women indicate increased risk, with CT or MRI used for precise quantification in specialist settings.

Directly measuring visceral fat requires imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI), which can accurately quantify the volume of intra-abdominal fat. However, these methods are expensive, involve radiation exposure (in the case of CT), and are not routinely used in clinical practice for this purpose. Dual-energy X-ray absorptiometry (DEXA) scanning can also provide estimates of fat distribution and is increasingly available in specialist settings.

In everyday clinical practice, waist circumference remains the most practical and widely recommended proxy measure for visceral fat. The NHS advises measuring at the midpoint between the lower rib and the top of the hip bone (iliac crest). NICE and the NHS recommend the following thresholds as indicators of increased health risk:

• Men: Waist circumference ≥94 cm (increased risk) and ≥102 cm (high risk)

• Women: Waist circumference ≥80 cm (increased risk) and ≥88 cm (high risk)

The waist-to-hip ratio and waist-to-height ratio offer additional context. NICE advises that a waist-to-height ratio below 0.5 is a useful target across all ethnic groups. This is particularly relevant for people from South Asian, Black African, or Black Caribbean backgrounds, who may carry greater metabolic risk at lower absolute waist measurements than these standard thresholds suggest.

Some consumer-grade body composition scales use bioelectrical impedance analysis (BIA) to estimate visceral fat levels and assign a numerical score. Whilst these devices can provide a general indication and support self-monitoring, their accuracy varies considerably between products and they are not validated for clinical decision-making. They should not be used as a substitute for clinical assessment.

If you are concerned about your visceral fat levels or have risk factors such as a family history of type 2 diabetes or cardiovascular disease, it is advisable to speak with your GP. In UK primary care, initial assessment typically includes blood pressure measurement, a fasting lipid profile, and HbA1c (glycated haemoglobin) as the first-line test for identifying raised blood glucose and diabetes risk. Fasting plasma glucose may be used where HbA1c is unsuitable (for example, in certain haematological conditions). Liver function tests may also be considered if there is a concern about NAFLD.

Lifestyle Changes to Reduce Visceral Fat

Visceral fat responds well to aerobic exercise, resistance training, and a Mediterranean-style diet; UK guidelines recommend at least 150 minutes of moderate-intensity activity per week alongside muscle-strengthening on two or more days.

The encouraging news is that visceral fat is generally more responsive to lifestyle intervention than subcutaneous fat. Evidence consistently shows that targeted changes to diet, physical activity, sleep, and stress management can lead to meaningful reductions in visceral fat, often before significant changes in overall body weight become apparent.

Dietary modifications are a cornerstone of visceral fat reduction. A diet rich in whole grains, vegetables, legumes, lean proteins, and healthy unsaturated fats — broadly consistent with a Mediterranean-style dietary pattern — is associated with reduced visceral fat. Conversely, diets high in refined carbohydrates, added sugars (particularly fructose), ultra-processed foods, and saturated fats are associated with greater visceral fat accumulation. Reducing alcohol intake is also important, as high alcohol consumption is associated with central fat deposition. NHS Live Well resources provide practical guidance on healthy eating and alcohol reduction.

Physical activity plays a particularly powerful role. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training are associated with reductions in visceral fat, including independently of overall weight loss. In line with the UK Chief Medical Officers' Physical Activity Guidelines, adults are advised to aim for:

• At least 150 minutes of moderate-intensity aerobic activity per week (or 75 minutes of vigorous-intensity activity)

• Muscle-strengthening activities on two or more days per week

Even modest increases in daily movement — such as reducing prolonged sitting — can have a beneficial effect on metabolic health.

Sleep quality and stress management are often overlooked but clinically relevant. Chronic sleep deprivation and elevated cortisol levels (associated with prolonged psychological stress) are both associated with increased visceral fat accumulation via hormonal pathways. Addressing these factors through sleep hygiene, mindfulness, or psychological support where appropriate can complement dietary and exercise interventions.

If lifestyle changes alone are insufficient, your GP can discuss further options. In the UK, this may include referral to a structured NHS weight-management programme (Tier 2 or Tier 3 services, depending on need and local availability). For eligible individuals, pharmacological treatment or bariatric surgery may be considered in line with current NICE guidance on obesity management. Your GP can advise on whether you meet the criteria for these interventions and help coordinate appropriate referral.

Frequently Asked Questions